Novel Oncologic Strategies in Osteosarcoma Management: Maximizing Impact, Minimizing Harm

DISCOVERIES (ISSN 2359-7232), 2025, volume 13

_{ORIGINAL ARTICLE}

_{FULL text (PDF)}

_{CITATION: Dohadwala TK, Abbas RH, Siji SM, Nadar S, Sakina, Jairath, Patel HA, Zurashvili T. Novel Oncologic Strategies in Osteosarcoma Management: Maximizing Impact, Minimizing Harm. Discoveries 2025, 13(3): e216. DOI: 10.15190/d.2025.15}

_{Novel Oncologic Strategies in Osteosarcoma Management: Maximizing Impact, Minimizing Harm}

Taha Kassim Dohadwala ¹, Rabab Hunaid Abbas ², Sharin Mary Siji ¹, Soumiya Nadar ^2, *, Sakina Sakina ², Naman Jairath ¹, Hetvi Ashwinkumar Patel ¹, Tinatin Zurashvili ³

• ¹ Department of Medicine, Faculty of Medicine, David Tvildiani Medical University, Tbilisi, Georgia
• ² Department of Medicine, Faculty of Medicine, Tbilisi State Medical University, Tbilisi, Georgia
• ³ Department of Medical Biochemistry, David Tvildiani Medical University, Tbilisi, Georgia

 * Corresponding author: Soumiya Nadar, Tbilisi State Medical University, Tbilisi, Georgia; Vazha-Pshavela, 0186, Tbilisi, Georgia. E-mail ID: soumiya.n2001@gmail.com; ORCID ID: 0009-0005-3456-3148

_Abstract

Doxorubicin (DOX), an anthracycline antibiotic, is pivotal in managing osteosarcoma (OS). Although a cornerstone in the multimodal treatment regimen, its usage is limited by its associated toxicities, such as cardiotoxicity, myelosuppression, and neurotoxicity. This review provides an in-depth discussion of the emerging research aimed at enhancing the overall efficacy and mitigating the undesired side effects of DOX in treating OS. We explore the various drug delivery systems, including polymer-based injectable hydrogels, hydroxyapatite-based systems, and various nanoparticle-based systems such as calcium carbonate nanocrystals and cerium-substituted hydroxyapatite. We also discuss various innovative combination therapies, such as pegylated liposomal DOX with cisplatin and DOX with platinum nanoparticles. Moreover, emerging research into light-sensitive nano-micelles have been highlighted. These methods improve DOX's cytotoxicity and potentially reduce the need for high systemic doses and their associated side effects. The review aims to highlight the promising future in OS treatment by integrating these methodologies to maximize the therapeutic action of DOX and reduce its systemic side effects.

_{Access FULL text of the manuscript here: FULL ARTICLE (PDF)}